Amphotericin B lipid preparations: what are the differences?

Adler-Moore, Jill; Proffitt, Richard T.

doi:10.1111/j.1469-0691.2008.01979.x

Cited by 102 publications

(65 citation statements)

References 92 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Lipid formulations (liposomal amphotericin B or amphotericin B lipid complex) are less nephrotoxic than conventional amphotericin B while retaining the drug's activity. 4,5 Clinical evidence for the combination of antimycotic drugs is limited and its use is experimental. 6,7 As HSCT recipients are often treated with multiple drugs, they are at risk for drug-drug interactions (DDIs) and adverse drug events (ADEs).…”

Section: Introductionmentioning

confidence: 99%

Drug interactions and adverse events associated with antimycotic drugs used for invasive aspergillosis in hematopoietic SCT

Egger

Meier

Leu

et al. 2009

Bone Marrow Transplant

View full text Add to dashboard Cite

The aim of this study was to assess the frequency of potential drug-drug interactions (pDDIs) and adverse drug events (ADEs) associated with antimycotics in hospitalized patients with hematopoietic SCT (HSCT). Of the 120 HSCT recipients evaluated, 36 received antimycotics. A total of 124 ADEs were recorded in 32 of the 36 patients treated, with 54 ADEs being possibly and 9 probably related to antimycotics. Of the treatments with amphotericin B, 93% were associated with one or more possible and 36% with probable ADEs. The corresponding figures for lipid-based amphotericin B were 100% and 7%, for voriconazole 68% and 11% and for caspofungin 70% and 0%. A total of 57 potentially severe DDIs associated with antimycotics were detected in 31 of the 36 patients. Of these, 14 DDIs were a possible cause of an ADE and 5 (4 times a combination of voriconazole with CYA and once a combination of CYA with conventional amphotericin B) were probably related. Although the prevalence of pDDIs and ADEs is high in HSCT patients, ADEs related with a high probability to treatment with antimycotics are rare. Regarding the high prevalence of pDDIs, our findings underscore the importance of close monitoring of laboratory and clinical parameters, as well as dose adjustment for critical drugs, in patients with HSCT.

show abstract

Section: Introductionmentioning

confidence: 99%

Drug interactions and adverse events associated with antimycotic drugs used for invasive aspergillosis in hematopoietic SCT

Egger

Meier

Leu

et al. 2009

Bone Marrow Transplant

View full text Add to dashboard Cite

show abstract

“…Table 1 shows the relationship of particle size vs. flow rate ratio (ratio between aqueous and solvent streams). It is clearthatwhen FRR increased, average size (D [4,3]) of particles decreased. The largest mean size of AmB lipid complexwas 33.1 µmatFRR of1:3.2.…”

Section: Discussionmentioning

confidence: 99%

“…The DSPG spectrum ( Figure 4A) Figure 4E) probably due to weakening or removing. This phenomenon could be due to electronic bond between group NH 3 + of AmB and P-O-of phospholipids.…”

Section: Ftirmentioning

confidence: 99%

See 1 more Smart Citation

A facile microfluidic method for production of amphotericin B lipid complex

Yen¹,

Duong²,

L³

et al. 2017

Pharm Sci Asia

View full text Add to dashboard Cite

Amphotericin B (AmB) is a large amphiphilic molecule, which is a drug of choice in therapy of systemic fungal infection because of its board-spectrum antifungal activity. However, conventional formulation of AmB is micelles, which is unstable in the bloodstream and releases drug to form toxic aggregates. Lipid complex of AmB has been developed to reduce toxicity while retaining activity. Microfluidic method is mixing technique, which permits millisecond mixing at the nano/microliter scale, can reproducibly generate limit size of particles of drug delivery system. In this study, microfluidic hydrodynamic focusing method was used to produce AmB lipid complex. It was obtained of two synthetic phospholipids: hydrogenated soy phosphatidylcholine (HSPC), distearoylphosphatidylglycerol (DSPG) and AmB in the molar ratio of 1:1:2.The lipid complex of AmB was characterized using differential scanning calorimetry (DSC), X -ray diffraction, Fourier-transform infrared spectroscopy (FTIR) and Field Emission Scanning Electron Microscopy(FESEM).The results showed that AmB lipid complex, prepared by microfluidic method, had smallest size at the flow rate ratio (FRR) of 5:1. The distinct phase transition temperature, the crystal peak of phospholipid, the characteristic band of-P-O-group of phospholipid were not observed in the DSC curve, X-ray diffraction diagram and FTIR spectra, respectively, of AmB lipid complex.

show abstract

“…Indeed, enhanced efficiency has been displayed by mice model (affected with chronic granulomatous disease and pulmonary IA) when administrated with combination of MCF (Mycamine) and AmpB [30] and in case of murine systemic aspergillosis, increased efficacy has been reported when treated with a combination of CAS plus AmpB or intra-lipid AmpB (LAmpB) [31]. Whereas, Clemons and Stevens [29] reported that there was no synergistic activity of MCF and AmpB for pulmonary IA in immunocompromised DBA/2 mice, although there was no antagonism too.…”

Section: Monotherapy/combination Therapy Of Echinocandins and Their Cmentioning

confidence: 99%

Echinocandins Versus Dated Antifungals in Combination Against Opportunistic Mycotic Infections

Narwal¹,

Balhara²,

Chaudhary³

et al. 2017

Asian J Pharm Clin Res

View full text Add to dashboard Cite

Scientific and clinical reports globally demonstrated that the opportunistic mycotic infections are at major risk to the human fitness. In the past few decades, the development of resistance in microbes to existing antifungals has emphasized on the search of new antimycotic drugs. As a matter of fact, "echinocandins" are new categories of broad-spectrum antifungal enlighten a hope in this direction. Echinocandins are bulky lipopeptides that inhibit the production of β-[1,3]-glucan "a major constituent of fungal cell wall" which ultimately leads to the death of fungal pathogens. In vitro as well as in vivo published reports have demonstrated that the echinocandins exhibit fungicidal activity against most Candida spp., while fungistatic against Aspergillus spp. and exclusively found to be more effective when tested in combination with polyenes/azoles. The present article is expert views on the recent and historical literature available on the antifungal therapies with accessing their impact on the human health. Emphasis is given to the utility of the echinocandins a potental antifungal agent by discussing recent examples of clinical and laboratory studies including the use of improved proteomics approaches to know a bit more about the interaction of human host and fungal pathogens.

show abstract

Amphotericin B lipid preparations: what are the differences?

Cited by 102 publications

References 92 publications

Drug interactions and adverse events associated with antimycotic drugs used for invasive aspergillosis in hematopoietic SCT

Drug interactions and adverse events associated with antimycotic drugs used for invasive aspergillosis in hematopoietic SCT

A facile microfluidic method for production of amphotericin B lipid complex

Echinocandins Versus Dated Antifungals in Combination Against Opportunistic Mycotic Infections

Contact Info

Product

Resources

About